Roche is reported to be planning to acquire Alexion, a company with a market cap of nearly $23 B after the rumor became public that Roche was interested. Alexion reportedly rebuffed any sale at this time but also engaged Goldman Sachs to help it lever up the offer or to fight any hostile takeover attempts.
For it's part, Roche wants products (and revenues). Alexion is the proud new papa of the blood medication, Soliris, that can sell for up to $400,000 per year per patient treated, and generated $1.1 B in 2012 sales. Alexion also has other desirable gems in the pipeline, including asfotase alpha.
At present, neither Roche nor Alexion will confirm that any overture by Roche ever took place -- nobody's kissing and telling. Though Roche supposedly has been in discreet conversations with Alexion for over a month and has sought financing for a potential deal.
Posted by Bruce Lehr July 30th 2013.